AccurECG™
FDA-cleared automated ECG interpretation for streamlined cardiac diagnostics
Software · Cloud SaaSCompany source
Company profile
About AccurKardia
AI-powered platform for cardiovascular disease detection and cardiac risk assessment.
Company description AccurKardia official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at AccurKardia?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cardiac arrhythmias
- Cardiovascular conditions
- Conditions detectable through ECG biomarkers beyond traditional cardiac applications
Who it serves
- Cardiologists
- Clinicians
- Healthcare providers
- Qualified healthcare professionals
Deployment & integration
Cloud Saas · Other deployment with recorded integration context.
Geographic context
MarketsUnited Kingdom · United States
Company sourceOfficial website
Company milestones
Platform expansion
FDA 510(k) clearance for AccurECG (K252361). Development of AK-AVS and AK+ Guard research applications (patent pending).
Partnerships
Recorded partners
- The Texas Heart Institute (through medical advisors Dr. Eduardo Hernandez and Dr. Matt Segar)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
AK-AVS™
Novel ECG application extending cardiac diagnostics beyond traditional capabilities
Software · OtherCompany source
AK+ Guard™
Investigational ECG technology for expanded cardiac condition detection
Software · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote MonitoringNCT07210021 · Sponsor · RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Improved patient outcomes
Through AI-powered ECG interpretation and biomarker detection
Lives saved
By transforming ECGs into more powerful diagnostic tools
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Juan C. Jimenez
Co-Founder & CEO
Mohamed Sadeq Ali
Co-Founder & COO
Dr. Naveed Razvi
Chief Medical Officer
Moin Hussaini
Chief Product Officer
Tony M Kuttiachen
Co-Founder & GM Cardiac Monitoring
Dr. Eduardo Hernandez
Medical Advisor
Dr. Matt Segar
Medical Advisor
Sanjiv Arora
Senior Advisor
06 · Company updates
Updates from AccurKardia
Recent articles published on AccurKardia's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.